[Skip to Navigation]
Invited Commentary
February 7, 2019

The Case for Extended Screening Intervals for People With Diabetes and No or Minimal Retinopathy at Baseline

Author Affiliations
  • 1Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia
  • 2Ophthalmology, University of Melbourne, Department of Surgery, Melbourne, Australia
  • 3Gloucestershire Retinal Research Group, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham General Hospital, Cheltenham, England
  • 4Oxford University Hospitals National Health Services Foundation Trust, John Radcliffe Hospital, Oxford, England
JAMA Ophthalmol. 2019;137(4):449-450. doi:10.1001/jamaophthalmol.2018.6901

The article by Modjtahedi et al1 in this issue of JAMA Ophthalmology is noteworthy because it adds to a growing body of evidence that suggests that extending screening intervals to 2 years for those with no or minimal diabetic retinopathy (DR) at baseline may be safe and appropriate. There is an increasing need for screening intervals to be informed by evidence and tailored to risk, given the aging population and the growing burden of diabetes.

Add or change institution